How much incident lung cancer was missed globally in 2012? An ecological country-level study

Abstract

Lung cancer incidence is increasing in many low-to-middle-income countries and is significantly under-reported in Africa, which could potentially mislead policy makers when prioritising disease burden. We employed an ecological correlation study design using countrylevel lung cancer incidence data and associated determinant data. Lagged prevalence of smoking and other exposure data were used to account for exposure-disease latency. A multivariable Poisson model was employed to estimate missed lung cancer in countries lacking incidence data. Projections were further refined to remove potential deaths from infectious/external competing causes. Global lung cancer incidence was much lower among females vs males (13.6 vs 34.2 per 100,000). Distinct spatial heterogeneity was observed for incident lung cancer and appeared concentrated in contiguous regions. Our model predicted a revised global lung cancer incidence in 2012 of 23.6 compared to the Globocan 2012 estimate of 23.1, amounting to ~38,101 missed cases (95% confidence interval: 28,489-47,713). The largest relative under-estimation was predicted for Africa, Central America and the Indian Ocean regions (Comoros, Madagascar, Mauritius, Mayotte, Reunion, Seychelles). Our results suggest substantial underreporting of lung cancer incidence, specifically in developing countries (e.g. Africa). The missed cost of treating these cases could amount to >US$ 130 million based on recent developing setting costs for treating earlier stage lung cancer. The full cost is not only under-estimated, but also requires substantial additional social/family inputs as evidenced in more developed settings like the European Union. This represents a major public health problem in developing settings (e.g. Africa) with limited healthcare resources.

MicroRNA‑214 upregulates HIF‑1α and VEGF by targeting ING4 in lung cancer cells

“…lung cancers are the most commonly diagnosed and most fatal type of cancers worldwide, of which non-small cell lung cancer (nSclc) accounts for ~80% of all primary lung cancer cases (1)(2)(3)(4). Since it has been reported that the majority of patients with nSclc are diagnosed at advanced stages, chemotherapeutics are widely applied as the main first-line agents for the treatment of these advanced stage nSclc patients in addition to surgical resection.…”

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

“…However, many developing countries lack a centralized reporting system, and it is stipulated that many cases of lung cancer go unreported, obscuring the real incidence of the disease. 9 The World Health Organization (WHO) estimates that lung cancer death rates worldwide will continue to rise, mainly as a result of an increase in global tobacco use, particularly in Asia. 10 In the United States, the incidence and death rates from lung cancer have been decreasing for men, and these numbers were initially rising for women until approximately 2000 and have since been leveling off.…”

PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype

“…Lung cancer is a heterogeneous group of diseases with respect to biology and clinical behavior and is one of the most common and aggressive cancers with the highest incidence and lethality. Indeed, the World Health Organization (WHO) has recently estimated a further increase worldwide in the coming years [ 1 , 2 ]. The most common lung cancer type is non-small cell lung cancer (NSCLC), representing about 85% of cases.…”